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M A J O R A R T I C L E
Interferon and Ribavirin Therapy for Chronic
Hepatitis C Virus Genotype 6: A Comparison
with Genotype 1
Chee-Kin Hui,1 Man-Fung Yuen,1 Erwin Sablon,2 Annie On-On Chan,1 Benjamin Chun-Yu Wong,1 and Ching-Lung Lai1
1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; 2Innogenetics, Ghent, Belgium
Because there is a lack of data on the treatment outcome of patients who carry hepatitis C virus (HCV)
genotype 6, we conducted a prospective study, to compare the effect of interferon and ribavirin therapy in
HCV genotypes 1 and 6, of patients with seropositive anti-HCV, persistently elevated alanine transaminase
levels, and detectable HCV RNA. Patients were treated with subcutaneous recombinant interferon a-2b and
ribavirin for 12 months. Of 40 patients, 16 had genotype 6, and 24 had genotype 1. An end-of-treatment
response was detected in 12 (75%) patients with genotype 6 and in 10 (41.6%) patients with genotype 1
( ). A sustained virological response (SVR) was present in 10 (62.5%) patients with genotype 6 and inPp .05
7 (29.2%) patients with genotype 1 ( ). Genotype 6 has a better response than genotype 1 and is associatedPp .04
with a higher SVR.
Hepatitis C virus (HCV) is a major cause of chronic
hepatitis, liver cirrhosis, and hepatocellular carcinoma
worldwide. HCV can induce chronic infection in ∼85%
of infected individuals [1]. Studies of HCV isolates col-
lected worldwide have documented significant genetic
variations [2]. On the basis of their genetic heteroge-
neity, it is now generally accepted that HCV has evolved
into 6 major genotypes, designated, in order of dis-
covery, as 1–6.
In Western Europe and the United States, the pre-
dominant genotypes are 1a, 1b, 2b, and 3a, with some
variation in frequency [3, 4]. In Japan and Taiwan, types
1b, 2a, and 2b are seen most frequently [4]. Elsewhere
in Asia, genotype 3 is the most common, whereas ge-
notype 4 is found most frequently in the Middle East
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and Africa [3, 4]. In Hong Kong, types 1a, 1b, 2b, 3,
and 6 have been reported to be the most common
genotypes [3, 4]. Of these 6 major genotypes, type 6a
shows one of the most confined geographical locations,
having been found only in Hong Kong, Macau, and
Vietnam or in emigrants from these countries [5]. Ge-
notype 6 has also been reported in Thailand [5].
As far as treatment is concerned, a number of studies
have demonstrated that pretreatment virus load and
genotype are independent predictors for the response
to treatment with interferon (IFN). The presence of
HCV genotype 2 or 3 has been associated with a greater
response to IFN, compared with genotype 1 [6, 7].
However, there has been a lack of data on the effect
of IFN and ribavirin in patients who have chronic hep-
atitis C disease with genotype 6, mainly because they
are predominantly found in Southeast Asia. We, there-
fore, conducted a study to compare the effect of IFN
and ribavirin therapy in HCV genotypes 1 and 6.
PATIENTS AND METHODS
From January 1999 to February 2001, Chinese patients
with chronic hepatitis C disease were recruited into our
1072 • JID 2003:187 (1 April) • Hui et al.
Table 1. Baseline demographic data of patients with hepatitis C virus (HCV) genotypes 6 and 1.
Factors
Genotype 6
(n p 16)
Genotype 1
(n p 24) P
Age, years (range) 44 (29–51) 50.5 (24–80) .06
Sex, M:F 12:4 18:6 .26
Bilirubin, mmol/L 10 (5–30) 10 (4–36) .87
ALP level, U/L 77 (60–111) 71 (48–106) .11
AST level, U/L 83 (39–275) 57 (33–290) .32
ALT level, U/L 120 (61–298) 90 (37–588) .17
HCV RNA level, 106 Eq/mL 6.05 (1–28.6) 1.015 (0.3–44.75) .22
Inflammatory activity before treatment, no. (%) of subjects .72
0–1 13 (81.3) 18 (75)
2–3 3 (18.8) 6 (25)
Stage of fibrosis before treatment, no. (%) of subjects .60
0–2 10 (62.5) 13 (54.2)
3 6 (37.5) 11 (45.8)
NOTE. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase.
prospective trial at the Department of Medicine, Queen Mary
Hospital, the University of Hong Kong (Hong Kong, China).
Patients recruited into the study fulfilled the following criteria:
(1) seropositive for anti-HCV by the third-generation ELISA
(Ortho Diagnostic Systems), (2) positive for HCV RNA by use
of a branched DNA assay (Quantiplex HCV-RNA 2.0 assay;
Chiron), (3) persistently elevated alanine transaminase (ALT)
levels (normal range, 6–53 U/L) on at least 3 occasions for at
least 6 months, and (4) features of chronic inflammation on
pretreatment liver biopsy specimens. Patients with advanced
liver cirrhosis, hemolytic disease, depression, autoimmune dis-
eases, hepatitis B virus infection, human immunodeficiency vi-
rus (HIV) infection, previous IFN therapy, and pregnancy were
excluded.
The HCV genotypes were determined using the VERSANT
HCV Genotype Assay (Bayer), following the manufacturer’s in-
structions. This line-probe assay contains specific probes, which
allows the determination of HCV genotypes 1–6 and its major
subtypes [8]. Patients with genotype 1 recruited into the present
study had their samples retested by amplification of part of the
HCV NS5B region and subsequent phylogenetic analysis that
used the GENEBASE program (Applied Maths) to confirm that
the samples were not genotypes 7, 8, or 9 mistyped as genotype
1, because this can affect the response of treatment [9]. For
phylogenetic analysis, a list of reference sequences was selected
from well-characterized full-genome sequences in the GenBank
database, covering all known genotypes and the major subtypes.
Patients recruited into the present study were treated with
subcutaneous recombinant IFN a-2b (Schering-Plough), 5 mU
3 times weekly, and oral ribavirin (Schering-Plough) 1000 or
1200 mg daily in 2 divided doses (1000 mg for those weighing
!75 kg and 1200 mg for those weighing 175 kg) for 12 months.
A percutaneous liver biopsy was performed at 1 month be-
fore treatment and 6 months after treatment. The specimens
were formalin fixed and reviewed by a pathologist blinded to
the biochemical, genotype, and HCV RNA data, according to
the method of Desmet et al. [10]. Improvement or progression
in posttreatment liver biopsy samples was classified as a change
in the score of 1.
The patients were followed-up regularly every 4 weeks while
receiving treatment and at 3 monthly intervals after treatment.
During each follow-up, complete blood counts, liver biochem-
istry, thyroid function test, and HCV RNA were checked. The
end-of-treatment response (ETR) was defined as undetecta-
ble HCV RNA at the end of treatment. A sustained virologi-
cal response (SVR) was defined as undetectable HCV RNA 6
months after the completion of treatment.
All statistical analyses were performed using SPSS 10.0 for
windows (SPSS). The Mann-Whitney U test was used for con-
tinuous variables with skewed distribution, a x2 test with Yates’s
correction and Fisher’s exact test were used for categorical var-
iables. All statistics were performed on the intent-to-treat pop-
ulation. Statistical significance was defined as .P ! .05
RESULTS
During this period, there were 196 anti-HCV–positive patients
with detectable HCV RNA being monitored in our clinic.
Among these patients, the genotypes detected were 1a (8.1%),
1b (54.7%), 2a (2.6%), 2b (0.5%), 3a (1.5%), 6a (21.9%), and
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Table 2. Baseline demographic data of patients with hepatitis
C virus (HCV) genotypes 6 and 1 who were not recruited into the
study.
Factor
Genotype 6
(n p 13)
Genotype 1
(n p 20)
Age, years (range) 53 (30–64) 57 (28–84)
Sex, M:F 9:4 12:8
Bilirubin level, mmol/L 9 (6–31) 12 (5–40)
ALP level, U/L 82 (65–124) 77 (41–123)
AST level, U/L 81 (49–269) 64 (45–278)
ALT level, U/L 143 (59–311) 110 (46–511)
HCV RNA level, 106 Eq/mL 7.10 (1.2–26.9) 1.21 (0.6–38.50)
NOTE. No significant difference was detected in the baseline demo-
graphic data between patients who did and did not receive therapy with ge-
notypes 1 or 6. ALP, alkaline phosphatase; ALT, alanine transaminase; AST,
aspartate transaminase.
6b (5.1%). Mixed and indeterminate genotypes were detected
in 5.6%. Of the 176 patients with genotypes 1 and 6, 56 (31.8%)
had normal ALT levels, 32 (18.2%) had previously received IFN
monotherapy, 6 (3.4%) had liver cirrhosis, 3 (1.7%) had un-
dergone liver transplantation, 3 (1.7%) had a history of Graves
disease, 2 (1.1%) had depression, and 1 (0.6%) had undergone
renal transplantation. Of the 73 patients who fulfilled the entry
criteria for our study, 40 (54.8%) were recruited—24 with ge-
notype 1 and 16 with genotype 6. The pretreatment demo-
graphic data between patients with genotypes 1 and 6 are shown
in table 1. There were no significant differences between the 2
groups (all P values were not significant [NS]). Even though
genotype 1 had a higher proportion of patients with F3 fibrosis,
compared with genotype 6, this difference was not significant
(P, NS).
The baseline demographic data for patients with genotypes
6 and 1 who were not recruited into our study are shown in
table 2. No significant difference was detected in the baseline
demographic data between patients with genotype 1 who did
and did not receive therapy (all P, NS). No significant difference
was also detected in the baseline demographic data between
patients with genotype 6 who did and did not receive therapy
(all P, NS).
At 24 weeks of treatment, 11 patients (68.8%) with genotype
6 had undetectable HCV RNA, whereas, of those with genotype
1, 8 patients (33.3%) had undetectable HCV RNA. A significant
difference could be detected when genotype 6 was compared
with genotype 1 ( ; odds ratio [OR], 4.40; 95% confi-Pp .02
dence interval [CI], 1.13–17.07).
At the end of treatment, 12 patients (75%) with genotype 6
had an ETR, whereas 10 patients (41.6%) with genotype 1 had
an ETR. There was a marginally significant difference in the
ETR between genotypes 6 and 1 ( ; OR, 4.20; 95% CI,Pp .05
1.04–16.90).
An SVR was present in 10 (62.5%) patients with genotype
6 and in 7 (29.2%) patients with genotype 1. A significant
difference between the SVR in patients with genotypes 6 and
1 could be detected ( ; OR, 4.05; 95% CI, 1.06–15.48).Pp .04
Posttreatment liver biopsy specimens showed improvement
in inflammatory activity in 4 (25%) patients with genotype 6
and in 3 (12.5%) patients with genotype 1 ( ). TherePp .41
was an improvement in the stage of fibrosis in 4 (25%) patients
with genotype 6 and in 2 (8.3%) patients with genotype 1
( ). Progression in the histology samples was detectedPp .20
in only 1 (6.3%) patient with genotype 6, whereas 3 (12.5%)
patients with genotype 1 had progression, as detected on liver
biopsy samples ( ). One (4.2%) patient with genotypePp .64
1 developed cirrhosis, whereas no patients with genotype 6 had
developed liver cirrhosis by the end of the study.
Five (12.5%) patients had a decrease in their hemoglobin
levels by 2 g/dL, but they did not require a reduction in the
dose of ribavirin. Only 2 (5%) patients had a decrease in he-
moglobin levels to !10 g/dL and required a reduction in the
dose of ribavirin. Three (7.5%) patients were withdrawn from
treatment because of thyrotoxicosis (2 patients) and depression
(1 patient).
DISCUSSION
In patients with chronic hepatitis C infection, combination
therapy with IFN and ribavirin for 48 weeks has an SVR rate
of 28%–31% in patients with genotype 1 and 64%–66% in
patients with genotype 2 or 3 [6, 7]. In those 2 studies, it was
also found that 64%–69% of patients with genotype 2 or 3 had
a sustained response to combination therapy, even with 6
months of treatment, whereas genotype 4 has been shown to
be associated with a poor SVR rate to combination therapy of
only 20% [11].
On the basis of these studies, it has been deduced that the
response of HCV to IFN and ribavirin is dependent on the
genotype. So far, there has been no study on the response to
combination therapy in patients with chronic HCV genotype
6. In Hong Kong, genotype 6 occurs in 27% of patients with
chronic HCV, and genotype 1b can be found in 58.8% [12].
Genotype 6 was reported to be particularly prominent among
patients with thalassaemia major and intravenous drug abusers
[13]. Genotypes 1 and 6 were the 2 most common genotypes
in our center, accounting for 62.8% and 27%, respectively, of
our patient population. In view of this, there is a need to
determine the response of combination IFN and ribavirin ther-
apy in genotypes 6 and 1 in Chinese people.
Our study compared the response to treatment for patients
with HCV genotypes 6 and 1. The dose of IFN used in the
present study was higher than that used in the 2 major regis-
tration trials [6, 7] of combination therapy for chronic hepatitis
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C disease, because there were data showing that a higher dose
of IFN may be more effective in the treatment of patients with
unfavorable viral characteristics [14]. As shown in table 1, there
were no significant differences in the demographic data of pa-
tients with genotype 6 versus those with genotype 1 in the
present study. In fact, the level of HCV viremia in patients with
genotype 6 in our study tended to be higher than that of ge-
notype 1, although this difference was not significant.
Our study showed that the ETR and SVR in genotype 6 were
75% and 62.5%, whereas, in genotype 1, they were only ∼41.6%
and 29.2%. This is similar to the response rate of genotype 1
from previous studies, even though the dose of IFN used in
the present study was 60% higher [6, 7]. This shows that, unlike
black Americans with genotype 1, who were less likely than
white Americans to respond to IFN treatment [15], Chinese
people with genotype 1 were not more refractory to treatment
and that a higher dose of IFN does not lead to a better SVR
in Chinese patients with genotype 1. Because the baseline char-
acteristics between the 2 genotypes were not significantly dif-
ferent, we can safely conclude that it is the genotype that plays
a more important role in determining response to therapy. To
the best of our knowledge, the present study is the largest to
have documented the response of genotype 6 to therapy. It is
also the largest study to have documented the response of Chi-
nese people with genotype 1 to therapy.
The study has a few limitations. First, there was a lack of
patients with genotype 6 randomized to receive 6 months of
therapy in order to determine the optimum duration of therapy
for genotype 6. Second, the number of patients studied was
small. Third, patients with genotype 1 were older than those
with genotype 6, even though this difference was not significant.
In conclusion, HCV genotype 6 has a better response to IFN
treatment than HCV genotype 1 and is associated with a sig-
nificantly higher SVR. A higher dose of IFN does not seem to
increase the SVR rate in Chinese patients with genotype 1.
Future trials should be performed to determine whether 6
months of combination therapy is adequate for patients with
genotype 6.
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